- Info
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
- Holders
Significant Ownership of BeOne Medicines Ltd.
- Signature - Title
- BeiGene, Ltd. - Chan Lee Senior Vice President, General Counsel
- Location
- Basel
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by BeOne Medicines Ltd..
Follow Filing Activity
Follow BeOne Medicines Ltd. and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of BeOne Medicines Ltd.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| LPTX | Leap Therapeutics, Inc. | Common Stock, par value $0.001 per share | 0% | $473,969 | 1,215,306 | BeiGene, Ltd. | 31 Oct 2024 |
Schedules 13D/G Reported by BeOne Medicines Ltd.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.